



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

Our STN: BLA 103795/5445

**SUPPLEMENT BLA APPROVAL**  
October 13, 2010

Amgen  
One Amgen Center Drive  
Mail Stop 17-2-B  
Thousand Oaks, CA 91320-1799

Attention: Marc Kubasak, Ph.D.  
Senior Manager, Regulatory Affairs

Dear Dr. Kubasak:

Please refer to your Supplemental Biologics License Application (sBLA), dated September 1, 2010, received September 2, 2010, submitted under section 351 of the Public Health Service Act for Enbrel (etanercept).

We acknowledge receipt of your risk evaluation and mitigation strategy (REMS) assessment dated September 1, 2010.

This Prior Approval labeling supplement to your biologics license application provides for proposed modifications to the approved REMS to remove Consumer Important Safety Information from dedicated REMS webpages and include demyelinating disorders (Guillain-Barré syndrome[GBS]) to the Medication Guide.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the Medication Guide) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. For administrative purposes, please designate this submission "**Product Correspondence – Final SPL for approved BLA STN 103795/5445.**"

Also within 14 days, amend all pending supplemental applications for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

The SPL will be accessible via publicly available labeling repositories.

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

### **RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for Enbrel (etanercept) was originally approved on June 23, 2008, and a REMS modification was approved on June 3, and July 20, 2010. The REMS consists of a Medication Guide, communication plan, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consist of removing Consumer Important Safety Information from dedicated REMS webpages and including demyelinating disorders (GBS) to the Medication Guide.

Your proposed modified REMS, submitted on September 1, 2010, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS will remain the same as that approved on June 3, 2010.

There are no changes to the REMS assessment plan described in our June 3, 2010, letter.

Assessments of an approved REMS must also include, under section 505-1(g)(3)(B) and (C), information on the status of any postapproval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. With respect to any such postapproval study, you must include the status of such study, including whether any difficulties completing the study have been encountered. With respect to any such postapproval clinical trial, you must include the status of such clinical trial, including whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trial have been encountered, and registration information with respect to requirements under subsections (i) and (j) of section 402 of the Public Health Service Act. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 601.70 and including any material or significant updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in section 505-1(g) could result in enforcement action.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to

the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

Prominently identify the submission containing the REMS assessments or proposed modifications with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**BLA 103795 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR BLA 103795  
PROPOSED REMS MODIFICATION  
REMS ASSESSMENT**

**NEW SUPPLEMENT (NEW INDICATION FOR USE)  
FOR BLA 103795  
REMS ASSESSMENT  
PROPOSED REMS MODIFICATION (if included)**

If you do not submit electronically, please send 5 copies of REMS-related submissions.

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (e.g., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this BLA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Ladan Jafari, Safety Regulatory Project Manager, at (301) 796-1231.

Sincerely,

/ Sally Seymour/

Sally Seymour, M.D.

Deputy Director for Safety

Division of Pulmonary, Allergy, and Rheumatology  
Products

Office of Drug Evaluation II

Center for Drug Evaluation and Research

ENCLOSURE(S):

Medication Guide, REMS and REMS materials